Para nosotros es importante involucrar a la próxima generación de científicos y médicos en nuestro trabajo.
Estamos encantados de trabajar con tres prometedores investigadores jóvenes en varios de nuestros estudios.
Investigadores Junior
2nd-Year Medical Student
Alyssa Ong
Alyssa Ong is a second-year medical student at the University of Washington School of Medicine. She is helping lead the estudio de detección de cáncer de riñón - una encuesta de proveedores de nefrología en los EE. UU., Australia y Nueva Zelanda que evaluó las prácticas actuales de detección de cáncer de riñón y las opiniones sobre posibles pautas de detección de cáncer de riñón.
A pesar de los riesgos más altos, no existen pautas de detección de cáncer de riñón en pacientes con enfermedad renal crónica y enfermedad renal en etapa terminal, incluidos aquellos en diálisis y con un trasplante de riñón.
UWSOM Graduate
Regina Tsay
Regina Tsay está ayudando a dirigir un análisis retrospectivo de los resultados en pacientes con discrasia de células plasmáticas (PCD) que son remitidos a la UW para trasplante de órganos.
Historically, about 50% of patients diagnosed with PCD develop kidney disease but are rarely referred for transplant due to concern for recurrence or progression of cancer after transplant. New therapies for PCD have enabled safer PCD and organ transplant care in the past decade. Yet, we lack contemporary referral and transplant data.
UW Senior
Shaaniya Mahabir
Shaaniya Mahabir planea ir a la escuela de medicina después de terminar sus estudios universitarios. Ella está trabajando en nuestro estudio Digital Spacing Profiling (DSP) en el rechazo mediado por anticuerpos (AMR).
La AMR sigue siendo la causa más formidable de fracaso del trasplante renal, con una comprensión limitada de las causas y, por lo tanto, opciones diagnósticas y terapéuticas limitadas. El perfil espacial digital de especímenes de biopsia renal es una tecnología novedosa que proporciona perfiles de proteína/ARN celular definidos espacialmente que pueden ayudar a definir mejor las causas de la AMR y los posibles objetivos terapéuticos.
ODESSA NATIONAL MEDICAL UNIVERSITY graduate
Harshana Liyanage
Harshana Liyanage graduated from Odessa National Medical University in Ukraine with a Medical Degree in General Medicine. He worked as a medical auditor under Quality Assurance for the oncology, hematology, and cardiology departments in Sri Lanka and also has experience as a hemodialysis technician.
Harshana helps maintain the CICT Bioregistry, extracting data from the electronic medical record and entering into the registry.
Second-year UW Medical Student
Qing Gao
Qing Gao earned a B.S. in biochemistry from Tufts University and worked as a research technician at Memorial Sloan Kettering before joining the UW MD-PhD program in 2024.
He is leading a study surveying provider practices and perspectives on anal cancer screening in transplant recipients. Despite the benefits of screening for anal cancer in high-risk patient populations, there has been limited implementation. Understanding current knowledge and barriers can lead to tangible improvements in anal cancer screening for SOTRs.
First-year UW Medical Student
Fatima Al-Shimari
Fatima Al-Shimari is a first-year medical student at the UWSOM, joining the CICT with a strong foundation in public health and research. Before medical school, she worked as an epidemiologist, contributing to research and policy efforts across infectious disease and population health.
Fatima is studying the use of immune checkpoint inhibitor in kidney transplant recipients with advanced skin cancers. Her contributions are helping advance knowledge of ICI safety and outcomes for complex patients with cancer and transplant.
UW Transplant Nephrology Fellow
Gaoyuan Huang
Gaoyuan is a transplant nephrology fellow at UW and served as the chief general nephrology fellow. She received her medical training at Tongji Medical College in Wuhan, China.
Gaoyuan is leading a project to characterize autoantibody profiles and their associations with oncologic and transplant outcomes. Immune checkpoint inhibitor (ICI) has revolutionized cancer treatment in the general population, their safety and effectiveness among the transplant patients remain uncertain with the risks of toxicity, transplant rejection and failure.
